Leaders in Pharmaceutical Business Intelligence (LPBI) Group

U.S. FDA advisers recommend approval of Cinqair (Reslizumab,Teva) asthma drug for adults

Reporter: Aviva Lev-Ari, PhD, RN

An advisory committee to the U.S. Food and Drug Administration recommended on Wednesday that the agency approve Teva Pharmaceutical Industries Ltd’s <TEVA.TA) experimental drug reslizumab for severe asthma in patients aged 18 and older.

The panel voted unanimously that the drug should not be approved for children aged 12 to 17.

Reslizumab is an antibody drug designed to be given intravenously once every four weeks.

The FDA, according to a Teva spokeswoman, is slated to decide by March whether to approve the drug, which would be sold under the brand name Cinqair.

The agency last month approved a similar asthma drug, Nucala, or mepolizumab, which is produced by GlaxoSmithKline Plc, for patients age 12 and older.

Sourced through Scoop.it from: www.reuters.com

See on Scoop.it – Cardiovascular Disease: PHARMACO-THERAPY